title: Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis?
abstract: OBJECTIVE
  According to National Institute of Health (NIH) criteria, a bladder capacity of less than 350 cc is an automatic exclusion for a diagnosis of Interstitial Cystitis (IC). In the present study, patients, showing symptoms of IC and with bladder capacities of <350 and >/=350 cc were tested as to their response to a intravesical hyaluronic acid therapy.
  
  
  METHODS
  The study included 48 patients with clinical symptoms of IC and a positive 0.4 M potassium sensitivity test. Maximum bladder capacity (C(max)) was assessed for the 0.9% NaCl solution first and then for the 0.2 M KCl solution. After the NaCl cystometry, patients were separated into two groups: Group I with a C(max) of <350 cc and Group II with a C(max) of >/=350 cc. Both groups were again separated in two further groups as to the respective percentage reduction of C(max) with the 0.2 M KCl solution: Group Ia/IIa (>/=30%) and Group Ib/IIb (<30%). Patients were treated with weekly instillations of 40 mg hyaluronic acid for 10 consecutive weeks. Pre- and post-treatment bladder symptoms were evaluated through their visual analog scale (VAS) scores.
  
  
  RESULTS
  With the saline solution, 32 patients had a C(max) of <350 cc (Group I), while 16 patients had a C(max) of >/=350 cc (Group II). Evaluation of VAS scores confirmed a positive response, i.e. symptom relief, to hyaluronic acid therapy, irrespective of bladder capacity. The improvement was particularly evident in patients with a C(max) reduction of >/=30% versus those with a reduction of <30% with the 0.2 M KCl solution (p=0.003).
  
  
  CONCLUSIONS
  The present study demonstrates that patients with typical IC symptoms and a cystometric bladder capacity of >/=350 cc, may have increased potassium sensitivity as a sign of IC and show symptom improvement after hyaluronic acid instillation therapy.
authors.affiliation: Department of Urology and Ludwig Boltzmann Institute of Urology and Andrology, Municipal Hospital Lainz, Wolkersbergenstrasse 1, A - 1130, Vienna, Austria. kurosch.daha@khl.magwien.gv.at
authors.forename: Lukas K
authors.initials: LK
authors.lastname: Daha
authors.forename: Claus R
authors.initials: CR
authors.lastname: Riedl
authors.forename: Dara
authors.initials: D
authors.lastname: Lazar
authors.forename: Gero
authors.initials: G
authors.lastname: Hohlbrugger
authors.forename: Heinz
authors.initials: H
authors.lastname: Pflüger
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018856:Cystitis, Interstitial / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis / Q000209:etiology; D010147:Pain Measurement; D011189:Potassium Chloride / Q000008:administration & dosage; D011446:Prospective Studies; D011788:Quality of Life; D012965:Sodium Chloride / Q000008:administration & dosage; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology*
chemical_list: D012965:Sodium Chloride; D011189:Potassium Chloride; D006820:Hyaluronic Acid